Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Boeke

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Child Psychiatry and Human Development|January 1, 1990
Combined medical and psychological treatment of hospitalized children with encopresisP M Dawson, K Griffith, K M Boeke
European Journal of Clinical Pharmacology|February 9, 2023
Dihydropyrimidine dehydrogenase phenotype in peripheral blood mononuclear cells is related to adverse events of fluoropyrimidine-therapyK R Doornhof, P D van der Linden, G M Boeke, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Child Psychiatry and Human Development|January 1, 1990
Combined medical and psychological treatment of hospitalized children with encopresisP M Dawson, K Griffith, K M Boeke
European Journal of Clinical Pharmacology|February 9, 2023
Dihydropyrimidine dehydrogenase phenotype in peripheral blood mononuclear cells is related to adverse events of fluoropyrimidine-therapyK R Doornhof, P D van der Linden, G M Boeke, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Pageof 1